NYSE:DVA DaVita (DVA) Stock Price, News & Analysis $138.44 -1.93 (-1.37%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$138.68 +0.24 (+0.17%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About DaVita Stock (NYSE:DVA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DaVita alerts:Sign Up Key Stats Today's Range$136.79▼$141.9750-Day Range$134.44▼$151.4752-Week Range$131.76▼$179.60Volume686,266 shsAverage Volume707,150 shsMarket Capitalization$10.45 billionP/E Ratio13.72Dividend YieldN/APrice Target$167.40Consensus RatingHold Company Overview DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado. Read More DaVita Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreDVA MarketRank™: DaVita scored higher than 87% of companies evaluated by MarketBeat, and ranked 114th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingHold Consensus RatingDaVita has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageDaVita has only been the subject of 1 research reports in the past 90 days.Read more about DaVita's stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth18.12% Earnings GrowthEarnings for DaVita are expected to grow by 18.12% in the coming year, from $10.76 to $12.71 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DaVita is 13.72, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.12.Price to Earnings Ratio vs. SectorThe P/E ratio of DaVita is 13.72, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.97.Price to Earnings Growth RatioDaVita has a PEG Ratio of 0.96. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioDaVita has a P/B Ratio of 28.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DaVita's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.17% of the float of DaVita has been sold short.Short Interest Ratio / Days to CoverDaVita has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in DaVita has recently decreased by 3.61%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDaVita does not currently pay a dividend.Dividend GrowthDaVita does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.06 Percentage of Shares Shorted8.17% of the float of DaVita has been sold short.Short Interest Ratio / Days to CoverDaVita has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in DaVita has recently decreased by 3.61%, indicating that investor sentiment is improving. News and Social Media2.2 / 5News Sentiment0.93 News SentimentDaVita has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for DaVita this week, compared to 12 articles on an average week.Search InterestOnly 3 people have searched for DVA on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, DaVita insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $352,650.00 in company stock.Percentage Held by InsidersOnly 2.00% of the stock of DaVita is held by insiders.Percentage Held by Institutions90.12% of the stock of DaVita is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DaVita's insider trading history. Receive DVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DaVita and its competitors with MarketBeat's FREE daily newsletter. Email Address DVA Stock News HeadlinesJames O. Hearty Sells 2,351 Shares of DaVita Inc. (NYSE:DVA) StockJuly 25, 2025 | insidertrades.comTruist Reduces PT on DaVita Inc. (DVA) from $170 to $164; Zacks Keeps ‘Hold’ RatingAugust 3 at 6:06 AM | msn.comTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada the 51st state because he’s desperate for critical minerals… They think his involvement in Ukraine is just another resource grab… They think his tariffs will wreck the economy… But they’re all missing the bigger picture. | Porter & Company (Ad)RadNet (NASDAQ:RDNT) versus DaVita (NYSE:DVA) Head to Head ComparisonAugust 3 at 2:04 AM | americanbankingnews.comContrasting Bioqual (OTCMKTS:BIOQ) & DaVita (NYSE:DVA)August 3 at 2:21 AM | americanbankingnews.comTruist Reduces PT on DaVita Inc. (DVA) from $170 to $164; Zacks Keeps ‘Hold’ RatingAugust 1 at 10:42 AM | finance.yahoo.com3 Reasons to Avoid DVA and 1 Stock to Buy InsteadJuly 23, 2025 | msn.comDaVita Inc. Schedules 2nd Quarter 2025 Investor Conference CallJuly 17, 2025 | prnewswire.comSee More Headlines DVA Stock Analysis - Frequently Asked Questions How have DVA shares performed this year? DaVita's stock was trading at $149.55 at the start of the year. Since then, DVA shares have decreased by 7.4% and is now trading at $138.44. How were DaVita's earnings last quarter? DaVita Inc. (NYSE:DVA) posted its quarterly earnings results on Monday, May, 12th. The company reported $2.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.75 by $0.25. The firm's revenue for the quarter was up 5.0% on a year-over-year basis. Read the conference call transcript. Does DaVita have any subsidiaries? The following companies are subsidiaries of DaVita: Northwest Physicians Network, Purity Dialysis, Family Health Care of Central Florida, Healthcare Partners, Gambro Healthcare, Aberdeen Dialysis LLC, Accountable Kidney Care LLC, and others. Who are DaVita's major shareholders? DaVita's top institutional shareholders include Allianz Asset Management GmbH (0.46%), Nordea Investment Management AB (0.37%), Wedge Capital Management L L P NC (0.36%) and VIRGINIA RETIREMENT SYSTEMS ET Al (0.20%). Insiders that own company stock include Javier Rodriguez, Michael David Staffieri, Joel Ackerman, Kathleen Alyce Waters, James O Hearty, Charles Berg, John M Nehra, Phyllis R Yale and Barbara J Desoer. View institutional ownership trends. How do I buy shares of DaVita? Shares of DVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DaVita own? Based on aggregate information from My MarketBeat watchlists, some other companies that DaVita investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings5/12/2025Today8/03/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - OUTP/HM CRE Sub-IndustryHealth Care Services Current SymbolNYSE:DVA CIK927066 Webwww.davita.com Phone(720) 631-2100Fax302-636-5454Employees76,000Year Founded1999Price Target and Rating Average Price Target for DaVita$167.40 High Price Target$184.00 Low Price Target$145.00 Potential Upside/Downside+20.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$10.09 Trailing P/E Ratio13.72 Forward P/E Ratio12.87 P/E Growth0.96Net Income$936.34 million Net Margins6.63% Pretax Margin11.14% Return on Equity176.11% Return on Assets4.66% Debt Debt-to-Equity Ratio23.18 Current Ratio1.25 Quick Ratio1.20 Sales & Book Value Annual Sales$12.82 billion Price / Sales0.82 Cash Flow$19.12 per share Price / Cash Flow7.24 Book Value$4.83 per share Price / Book28.66Miscellaneous Outstanding Shares75,500,000Free Float73,990,000Market Cap$10.45 billion OptionableOptionable Beta1.09 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NYSE:DVA) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersWall Street Laughed. Now They're Buying.For six months, I’ve been pounding the table on a major gold miner—while Twitter pundits laughed. But now, the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Create New Advertiser | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOut with the old (A.I.) - In with the new (E.I.)One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredStrange twist to Bitcoin’s rallyThe #1 crypto to buy today Better than Bitcoin? (top crypto for less than $1) Over the past 15 years, B...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DaVita Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DaVita With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.